Company intelligence
Insilico Medicine
#insilicomeds, #drugdiscovery, #ai, #oncology, #RL, #DL #aging, #longevity #biologics #LLMS #AIDD
About Insilico Medicine
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
Verified activity
Signals from Insilico Medicine
13 published signals
Presence & Recognition
Insilico Medicine is hosting an exclusive Pharma AI Q3 Fall Update showcasing Generative Biologics, Chemistry42, and PandaOmics platforms.
Reported by Insilico Medicine
Research & Knowledge
Insilico Medicine released new SOTA+ drug discovery models for drug safety and metabolism prediction, including InsilicoMMAI-Chem-ADMET, which reaches SOTA+ performance on 7 ADMET tasks.
Reported by Insilico Medicine
Presence & Recognition
Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD, joined Bloomberg’s The China Show with Yvonne Man and Avril Hong to discuss how AI-discovered candidate for Idiopathic Pulmonary Fibrosis (IPF) reduced participants' biological age by 3 to 6 years.
Reported by Insilico Medicine
Presence & Recognition
Insilico Medicine Senior Vice President of Clinical Development Carol Ann Satler MD PhD participated in an event at ERS2026 in Barcelona.
Reported by Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP
Presence & Recognition
Insilico Medicine convened the Rentosertib Scientific Advisory Board during the European Respiratory Society ERS 2026 meeting in Barcelona to discuss its Phase III oral program and Phase I inhalation program for IPF.
Reported by Insilico Medicine
Research & Knowledge
Insilico Medicine published a study in Nature Biotechnology showing that six independently developed proteomic aging clocks found that six independently developed proteomic aging clocks all pointed in the same direction: IPF patients treated with RENTOSERTIB showed a reduction in predicted biological age after four weeks in one dosing group.
Reported by Insilico Medicine
Presence & Recognition
Insilico Medicine Senior Vice President of Global Clinical Development Carol Ann Satler participated in the industry panel AI Innovation in Healthcare: What Pharma Leaders Need to Know as part of Eli Lilly and Company's inaugural AI Strategy & Transformation Program at Harvard Business School.
Reported by Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP
Research & Knowledge
Insilico Medicine introduced TargetPro+ as a new generation of state-of-the-art models for target identification, achieving 83% accuracy across 8 disease areas.
Reported by Insilico Medicine
Research & Knowledge
Insilico Medicine introduced TargetPro+ as a new generation of state-of-the-art models for target identification, achieving 83% accuracy across 8 disease areas.
Reported by Insilico Medicine
Research & Knowledge
Insilico Medicine was featured in a Forbes/BernardMarr.com article by Bernard Marr exploring how the company is moving past early AI proofs-of-concept to build a repeatable, scalable engine for biopharma innovation.
Reported by Insilico Medicine
Presence & Recognition
Insilico Medicine's Dr. Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP joined an industry panel on AI Innovation in Healthcare: What Pharma Leaders Need to Know during Lilly's inaugural AI Strategy & Transformation Program at Harvard Business School.
Reported by Insilico Medicine
Presence & Recognition
Insilico Medicine Co-Founder and President Alex Aliper, PhD, will be featured across two high-impact sessions at AIM Congress 2026 in Dubai focusing on longevity therapeutics and the future of the AI innovation economy.
Reported by Insilico Medicine
Presence & Recognition
Insilico Medicine is hosting the AWS AI League Drug Discovery Challenge during Boston AI Week on October 2, featuring a hands-on build event where teams will fine-tune a Small Language Model to predict drug discovery properties.
Reported by Insilico Medicine